Login

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q3 FY2023
As of Sep 30, 2023
Q2 FY2023
As of Jun 30, 2023
Q1 FY2023
As of Mar 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q3 FY2022
As of Sep 30, 2022
Q2 FY2022
As of Jun 30, 2022
Q1 FY2022
As of Mar 31, 2022
Q4 FY2021
As of Dec 31, 2021
Q3 FY2021
As of Sep 30, 2021
Q2 FY2021
As of Jun 30, 2021
Q1 FY2021
As of Mar 31, 2021
Q4 FY2020
As of Dec 31, 2020
Q3 FY2020
As of Sep 30, 2020
Q2 FY2020
As of Jun 30, 2020
Assets
Current assets
Cash
Cash and cash equivalents
Accounts receivable, net of allowance of $2,086 and $2,028 as of September 30, 2023 and December 31, 2022, respectively
Inventories
Prepaid expenses and other current assets
Receivable from related party
Total current assets
Cash and marketable securities held in Trust Account
Interest receivable on cash and marketable securities held in the Trust Account
Property and equipment, net
Operating lease right-of-use asset, net
Other assets
Total assets
Liabilities and stockholders’ equity
Current liabilities
Accounts payable
Accrued expenses and other current liabilities
Warrant liability
Derivative liability
Current portion of operating lease obligation
Current portion of finance lease obligation
Current debt, net of debt discount
Current portion of long-term debt - related party
Accrued liabilities
Other current liabilities
Total current liabilities
Deferred underwriting fee payable
Warrant liability
Long-term debt, convertible note net of debt discount
Long-term debt, net of current portion and debt discount - related party
Long-term debt, net of debt discount
Operating lease obligation, net of current portion
Derivative liability
Earnout liability
Other long-term liabilities
Total liabilities
Common stock subject to possible redemption, 18,421,231 and 18,431,618 shares as of March 31, 2021 and December 31, 2020, respectively, at a redemption value of $10.10 per share
Stockholders’ (deficit) equity
Preferred stock, par value $0.0001, 1,000,000 shares authorized and no shares issued and outstanding as of September 30, 2023 and December 31, 2022
Common stock, par value $0.0001, 250,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 6,593,516 and 4,492,157 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders’ (deficit) equity
Total liabilities and stockholders’ (deficit) equity

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support